BioMarin Pharmaceuticals Inc (BMRN) — Analysis Summary
BioMarin Pharmaceuticals Inc (BMRN) has a market cap of $11.44B with year-over-year revenue growth of +12.9%. Net margin stands at 10.8%. The stock trades at a P/E ratio of 42.6.
Key Takeaways
- Revenue changed +12.9% year-over-year
- Net margin of 10.8%
- P/E ratio of 42.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, BMRN posted revenue growth of +12.9% and trades at a P/E of 42.6.
BioMarin Pharmaceuticals Inc (BMRN)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
3,221
Headquarters
NOVATO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.